Rasha Aboelhassan: Why should we test NGS for all lung cancer patients as early as possible
shared a post on LinkedIn:
“For decades, advance lung cancer was known as a lethal disease, a few years ago NGS changed this bad reputation, by highliting the subtype of lung cancer and later, researchers can define the target therapy for each lug cancer subtype.
This research do not only describe the different survival outcomes between patients with known mutation and unknown mutation, investigator also highlighted that patients with known mutation but did not have chance for targeted therapy had a different bad outcomes.
In this research, there is also new data about: why should we test NGS for all lung cancer patients as early as possible.
Survival outcomes are significantly better for patients who know their results earlier and had their targeted therapy earlier.
Thanks to all investigators who worked on this publication in International Journal of Molecular Sciences MDPI.”
Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination
Authors: Po-Hsin Lee , Wei-Fan Ou, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
Source: Rasha Aboelhassan/LinkedIn
Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field and is in the Editorial Staff of Egyptian Journal of Human Genetics.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023